NCT01063283View on ClinicalTrials.gov

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions
DRUG

Pemetrexed

Pemetrexed 500 mg/m\^2 intravenously over 10 minutes

DRUG

Carboplatin

Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes

DRUG

Bevacizumab 7.5 mg/kg

Bevacizumab at 7.5 mg/kg intravenously over 90 minutes

DRUG

Bevacizumab 15 mg/kg

Bevacizumab at 15 mg/kg intravenously over 90 minutes

Trial Locations (3)

60201

North Shore University Health System, Evanston

60426

Ingalls Memorial Hospital, Harvey

60637

The University of Chicago Medical Center, Chicago

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Chicago

OTHER